MA41119A - Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique - Google Patents
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastiqueInfo
- Publication number
- MA41119A MA41119A MA041119A MA41119A MA41119A MA 41119 A MA41119 A MA 41119A MA 041119 A MA041119 A MA 041119A MA 41119 A MA41119 A MA 41119A MA 41119 A MA41119 A MA 41119A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- methods
- sideroblastic anemia
- myelodysplasic syndromes
- myelodysplasic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462086977P | 2014-12-03 | 2014-12-03 | |
US201462088087P | 2014-12-05 | 2014-12-05 | |
US201562155395P | 2015-04-30 | 2015-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41119A true MA41119A (fr) | 2017-10-10 |
Family
ID=56092498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041119A MA41119A (fr) | 2014-12-03 | 2015-12-02 | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
Country Status (11)
Country | Link |
---|---|
US (3) | US10189882B2 (fr) |
EP (1) | EP3226887B1 (fr) |
JP (2) | JP6737786B2 (fr) |
KR (1) | KR102603899B1 (fr) |
CN (1) | CN107405383A (fr) |
AU (2) | AU2015358398B2 (fr) |
CA (1) | CA2969413A1 (fr) |
HK (1) | HK1247115A1 (fr) |
MA (1) | MA41119A (fr) |
TW (2) | TWI758237B (fr) |
WO (1) | WO2016090188A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
CA2890217C (fr) | 2012-11-02 | 2021-07-20 | Yifu FANG | Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres |
EP3154566B1 (fr) * | 2014-06-13 | 2022-08-03 | Acceleron Pharma Inc. | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ActRIIアンタゴニスト及び貧血を治療するための使用 |
WO2016187378A1 (fr) | 2015-05-20 | 2016-11-24 | Celgene Corporation | Procédés de culture de cellules in vitro pour la bêta-thalassémie à l'aide de pièges à ligands du récepteur de l'activine de type ii |
WO2017079591A2 (fr) | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Méthodes pour augmenter les taux d'érythrocytes et traiter l'érythropoïèse inefficace |
AU2016359695A1 (en) | 2015-11-23 | 2018-06-14 | Acceleron Pharma Inc. | Methods for treating eye disorders |
WO2018089715A1 (fr) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Variants de type iia du récepteur de l'activine et leurs méthodes d'utilisation |
EP3706777A4 (fr) | 2017-11-09 | 2021-06-23 | Keros Therapeutics, Inc. | Variants de type iia du récepteur de l'activine et leurs méthodes d'utilisation |
EP3737406A4 (fr) | 2018-01-12 | 2021-11-03 | Keros Therapeutics, Inc. | Variants de type iib du récepteur de l'activine et leurs méthodes d'utilisation |
CN108113965A (zh) * | 2018-01-25 | 2018-06-05 | 苏州科技城医院 | 一种氟碳化合物脂质体及其制备方法 |
KR20210088548A (ko) * | 2018-10-31 | 2021-07-14 | 셀진 코포레이션 | 액티빈-actrii 리간드 트랩을 사용하는 고리 철적혈모구가 있는 대상체에서 매우 낮은, 낮은 또는 중간 위험 골수이형성 증후군으로 인한 빈혈의 치료 |
WO2021189010A1 (fr) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Procédés d'utilisation de variants de récepteur de l'activine de type iib |
EP4121090A1 (fr) * | 2020-03-20 | 2023-01-25 | Keros Therapeutics, Inc. | Procédés d'utilisation de variants du récepteur de l'activine de type iia |
CN113604562B (zh) * | 2020-05-05 | 2024-01-02 | 北京市神经外科研究所 | Sf3b1基因突变在泌乳素型垂体腺瘤辅助诊断中的应用 |
US20230210827A1 (en) * | 2020-05-15 | 2023-07-06 | Celgene Corporation | Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors |
WO2022271716A2 (fr) * | 2021-06-21 | 2022-12-29 | Keros Therapeutics, Inc. | Procédés d'utilisation d'inhibiteurs de la signalisation du type ii du récepteur de l'activine |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
WO1990008822A1 (fr) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Recepteur d'erythropoietine |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
US5707796A (en) | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
DK0786469T3 (da) | 1990-06-11 | 2006-07-10 | Gilead Sciences Inc | Nukleinsyreligander |
US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP1997894B1 (fr) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Protéine de liaison biosynthétique pour un marqueur du cancer |
US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
CA2217545A1 (fr) | 1995-04-11 | 1996-10-17 | Marc Vidal | Systemes d'hybrides doubles inverses |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6699843B2 (en) | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
US6011577A (en) | 1997-06-30 | 2000-01-04 | Polaroid Corporation | Modular optical print head assembly |
WO1999010364A1 (fr) | 1997-08-29 | 1999-03-04 | Human Genome Sciences, Inc. | Follistatine-3 |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
CA2355215A1 (fr) | 1998-12-28 | 2000-07-06 | Jim Wells | Identification de ligands de type petites molecules organiques, destines a former des liaisons |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
JP2003517580A (ja) | 1999-01-21 | 2003-05-27 | メタモーフイクス・インコーポレーテツド | 増殖分化因子インヒビター及びそれらの用途 |
ATE428719T1 (de) | 1999-07-29 | 2009-05-15 | Gilead Sciences Inc | Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors |
WO2001044463A1 (fr) | 1999-12-15 | 2001-06-21 | Genentech, Inc. | Balayage aveugle, procede combinatoire permettant la representation d'epitopes de proteines fonctionnelles |
JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CN101940189A (zh) | 2000-11-30 | 2011-01-12 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
CA2501936A1 (fr) | 2002-10-15 | 2004-04-29 | Celgene Corporation | Methode d'utilisation de medicaments selectifs inhibiteurs des cytokines et compositions comprenant des medicaments selectifs inhibiteurs des cytokines pour le traitement et la prise en charge de syndromes myelodysplastiques |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
EP1585767A2 (fr) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Banques de phages anticorps synthetiques |
US20070135336A1 (en) | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP2360186B1 (fr) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anticorps dirigés contre la sélectine P |
CA2891010C (fr) | 2004-07-23 | 2022-09-20 | Acceleron Pharma Inc. | Polypeptides du recepteur actrii, procedes et compositions correspondants |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
US7879569B2 (en) | 2004-11-09 | 2011-02-01 | The Trustees Of The University Of Pennsylvania | Methods for diagnosis of myelodysplastic syndromes (MDS) |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
EP1957531B1 (fr) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl |
JP5261187B2 (ja) | 2005-11-23 | 2013-08-14 | アクセルロン ファーマ, インコーポレイテッド | アクチビン−ActRIIaアンタゴニストおよび骨成長を促進するための使用 |
EP1973951A2 (fr) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Polypeptides de liaison avec des sequences de diversite limitees |
TW200812616A (en) | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
WO2008030367A2 (fr) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Inhibiteurs sélectifs de la myostatine |
US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
CN105582521A (zh) * | 2006-12-18 | 2016-05-18 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
MX2009008222A (es) * | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. |
TW202021980A (zh) | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
WO2009158035A2 (fr) | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Procédés pour administrer un antagoniste d’activine-actriia et surveiller des patients traités |
HUE051137T2 (hu) * | 2008-08-14 | 2021-03-01 | Acceleron Pharma Inc | GDF-csapdák |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
RU2642302C1 (ru) * | 2009-08-13 | 2018-01-24 | Акселерон Фарма Инк. | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов |
EP2412798A1 (fr) | 2010-07-27 | 2012-02-01 | Gambro Lundia AB | Membrane biomimétique pour cultiver des cellules |
ES2869168T3 (es) * | 2011-10-17 | 2021-10-25 | Acceleron Pharma Inc | Composiciones para tratar la mielofibrosis |
NZ747350A (en) * | 2012-10-24 | 2020-07-31 | Celgene Corp | Methods for treating anemia |
WO2015143403A1 (fr) | 2014-03-21 | 2015-09-24 | Acceleron Pharma, Inc. | Méthodes pour augmenter les taux d'érythrocytes et traiter l'érythropoïèse inefficace par inhibition de l'activine b et/ou de gdf11 |
MA52909A (fr) | 2014-04-18 | 2021-04-21 | Acceleron Pharma Inc | Procédés d'augmentation des taux de globules rouges et de traitement de la drépanocytose |
EP3154566B1 (fr) | 2014-06-13 | 2022-08-03 | Acceleron Pharma Inc. | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ActRIIアンタゴニスト及び貧血を治療するための使用 |
MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
JOP20160092B1 (ar) | 2015-05-13 | 2023-03-28 | Celgene Corp | علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية |
CN116327952A (zh) | 2015-08-04 | 2023-06-27 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
-
2015
- 2015-12-02 MA MA041119A patent/MA41119A/fr unknown
- 2015-12-03 KR KR1020177017082A patent/KR102603899B1/ko active IP Right Grant
- 2015-12-03 EP EP15865103.4A patent/EP3226887B1/fr active Active
- 2015-12-03 WO PCT/US2015/063835 patent/WO2016090188A1/fr active Application Filing
- 2015-12-03 CN CN201580075439.3A patent/CN107405383A/zh active Pending
- 2015-12-03 TW TW104140598A patent/TWI758237B/zh active
- 2015-12-03 US US14/958,551 patent/US10189882B2/en active Active
- 2015-12-03 JP JP2017529349A patent/JP6737786B2/ja active Active
- 2015-12-03 AU AU2015358398A patent/AU2015358398B2/en active Active
- 2015-12-03 CA CA2969413A patent/CA2969413A1/fr active Pending
- 2015-12-03 TW TW111105042A patent/TW202220689A/zh unknown
-
2018
- 2018-05-25 HK HK18106801.6A patent/HK1247115A1/zh unknown
- 2018-12-05 US US16/210,525 patent/US10829531B2/en active Active
-
2020
- 2020-07-16 JP JP2020121986A patent/JP2020169217A/ja active Pending
- 2020-10-01 US US17/060,989 patent/US20210230239A1/en not_active Abandoned
-
2021
- 2021-12-23 AU AU2021290319A patent/AU2021290319A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2016090188A1 (fr) | 2016-06-09 |
JP2017537921A (ja) | 2017-12-21 |
US10189882B2 (en) | 2019-01-29 |
TW202220689A (zh) | 2022-06-01 |
US10829531B2 (en) | 2020-11-10 |
TWI758237B (zh) | 2022-03-21 |
US20160289286A1 (en) | 2016-10-06 |
TW201636043A (zh) | 2016-10-16 |
EP3226887A1 (fr) | 2017-10-11 |
JP2020169217A (ja) | 2020-10-15 |
KR20170088927A (ko) | 2017-08-02 |
EP3226887A4 (fr) | 2018-08-08 |
AU2021290319A1 (en) | 2022-02-03 |
HK1247115A1 (zh) | 2018-09-21 |
US20190233486A1 (en) | 2019-08-01 |
EP3226887B1 (fr) | 2024-03-27 |
CA2969413A1 (fr) | 2016-06-09 |
JP6737786B2 (ja) | 2020-08-12 |
AU2015358398A1 (en) | 2017-06-15 |
AU2015358398B2 (en) | 2021-10-07 |
KR102603899B1 (ko) | 2023-11-17 |
CN107405383A (zh) | 2017-11-28 |
US20210230239A1 (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41119A (fr) | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
MA46102A (fr) | Composés de tétracycline et méthodes de traitement | |
MA41028A (fr) | Méthodes et formulations pour le traitement de pathologies oculaires vasculaires | |
MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
MA45563A (fr) | Méthodes de traitement du cancer de l'ovaire | |
MA45192A (fr) | Traitement d'association | |
MA52371A (fr) | Méthodes de traitement d'infections dues aux coronaviridae | |
MA40867A (fr) | Méthodes pour le traitement d'infections virales à filoviridae | |
MA43374A (fr) | Méthodes de traitement de tumeurs malignes | |
DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
MA43190A (fr) | Traitement de la dyslipidémie mixte | |
MA49715A (fr) | Oligomères et conjugués d'oligomères | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
FI20155065A (fi) | Monikäyttölaite eläimen hoitoon | |
SG11201609652RA (en) | Treatment of polybacterials infections | |
MA53882A (fr) | Méthodes de traitement de la sclérose en plaques | |
MA43134A (fr) | Compositions et méthodes de transduction tumorale | |
MA45675A (fr) | Méthodes et compositions permettant le traitement du cancer | |
DK3506904T3 (da) | Behandling af demens | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
MA48730A (fr) | Compositions et méthodes de traitement de synucléinopathies | |
MA43230A (fr) | Méthodes et compositions pour le traitement d'une épidermolyse bulleuse | |
GB201618424D0 (en) | Treatment of antibody mediated disease |